Notably, co-infusion of the selective GIPR antagonist GIP(3–30)NH2 only partially attenuated CTX suppression, possibly due to incomplete receptor blockade in bone, residual effects of hyperglycemia or insulin, or the short infusion duration. The gene discussed is GIP; the disease is Hyperglycemia.